Merck Millipore and Proteomics International collaborate over protein biomarkers
Merck Millipore has announced a collaboration with Proteomics International to validate biomarkers related to diabetic nephropathy.
Merck Millipore has announced a collaboration with Proteomics International to validate biomarkers related to diabetic nephropathy.
The union will allow Proteomics International to assess its 13 newly identified putative protein biomarkers, that include proteins involved in metabolism, inflammation and oxidative stress, using Merck Millipore’s multiplex immunoassays. This will mean that, once validated, the biomarkers could be used to effectively monitor the progression and prognosis of kidney disease in patients with diabetes.
Jehangir Mistry, PhD, director of R&D at Merck Millipore, said, “We expect this opportunity will enable Merck Millipore to expand our substantial portfolio of Elisa and Milliplex multiplexed-bead based assays for diabetes and metabolic disease biomarkers.”
Richard Lipscombe, PhD, managing director of Proteomics International, commented, “We chose to partner with Merck Millipore because of their extensive portfolio of developed protein biomarkers and custom assay development expertise. We are very excited to be working with them to progress our initial discovery of these biomarkers that could improve diagnosis and health outcomes on such a large scale.”
For more information please visit ref="http://www.millipore.com">www.millipore.com
Prioritizing Non-Target Screening in LC–HRMS Environmental Sample Analysis
April 28th 2025When analyzing samples using liquid chromatography–high-resolution mass spectrometry, there are various ways the processes can be improved. Researchers created new methods for prioritizing these strategies.
Free Poster: NDSRI Risk Assessment and Trace-Level Analysis of N-Nitrosamines
April 25th 2025With increasing concern over genotoxic nitrosamine contaminants, regulatory bodies like the FDA and EMA have introduced strict guidelines following several high-profile drug recalls. This poster showcases a case study where LGC and Waters developed a UPLC/MS/MS method for quantifying trace levels of N-nitroso-sertraline in sertraline using Waters mass spectrometry and LGC reference standards.
New TRC Facility Accelerates Innovation and Delivery
April 25th 2025We’ve expanded our capabilities with a state-of-the-art, 200,000 sq ft TRC facility in Toronto, completed in 2024 and staffed by over 100 PhD- and MSc-level scientists. This investment enables the development of more innovative compounds, a broader catalogue and custom offering, and streamlined operations for faster delivery. • Our extensive range of over 100,000 high-quality research chemicals—including APIs, metabolites, and impurities in both native and stable isotope-labelled forms—provides essential tools for uncovering molecular disease mechanisms and exploring new opportunities for therapeutic intervention.
